Regeneron Pharmaceuticals, Inc.

REGN · NASDAQ · USD

PoliticiansInstitutionalInsiders

Current holders

Politician	Disclosed
Donald Trump R · EXECUTIVE	net −$113K – $328K 8 disclosures · 5 bought / 3 sold · last Jul 23, 2026
Ro Khanna D · HOUSE · CA	−$457K – $537K −$677K – $877K today 66 filings · last Jul 7, 2026
Gilbert Ray Cisneros, Jr. D · HOUSE · CA	−$12K – $44K −$12K – $81K today 4 filings · last May 15, 2026
Donald S. Beyer, Jr. D · HOUSE · VA	−$41K – $57K −$53K – $79K today 7 filings · last Feb 28, 2022
Alan Armstrong R · SENATE · OK	$1K – $15K $1K – $16K today 1 filing · last Mar 27, 2026
Steve Chabot R · HOUSE · OH	$1K – $15K $2K – $24K today 1 filing · last May 26, 2015
Julia Letlow R · HOUSE · LA	$1K – $15K $1K – $15K today 1 filing · last Feb 12, 2026
Greg Landsman D · HOUSE · OH	−$14K – $14K −$11K – $14K today 2 filings · last Oct 15, 2024
Tommy Tuberville R · SENATE · AL	−$28K – $28K −$28K – $38K today 4 filings · last Apr 4, 2024
Dean Phillips D · HOUSE · MN	−$42K – $42K −$77K – $107K today 6 filings · last May 13, 2020

Recent transactions

Trades from Jan 15, 2025 – Jul 23, 2026

Politician	Type	Filed after	Amount
Donald Trump R · EXECUTIVE	Buy	61 days Jul 23, 2026 → Sep 22, 2026	≥$50K
Donald Trump R · EXECUTIVE	Buy	67 days Jul 17, 2026 → Sep 22, 2026	≥$1K
Donald Trump R · EXECUTIVE	Sell	67 days Jun 16, 2026 → Aug 22, 2026	≥$1K
Donald Trump R · EXECUTIVE	Sell	71 days Jun 12, 2026 → Aug 22, 2026	≥$100K
Ro Khanna D · HOUSE · CA-17	Buy	31 days Jul 7, 2026 → Aug 7, 2026	≥$1K
Alan Armstrong R · SENATE · OK	Buy	116 days Mar 27, 2026 → Jul 21, 2026	≥$1K
Ro Khanna D · HOUSE · CA-17	Buy	20 days Jun 16, 2026 → Jul 6, 2026	≥$1K
Ro Khanna D · HOUSE · CA-17	Sell	34 days Jun 2, 2026 → Jul 6, 2026	≥$1K
Donald Trump R · EXECUTIVE	Sell	44 days May 18, 2026 → Jul 1, 2026	≥$1K
Donald Trump R · EXECUTIVE	Buy	51 days May 11, 2026 → Jul 1, 2026	≥$100K

Congressional trading data provided by QuiverQuant

Institutional

Investors holding

1,397

13F shares

92.3M

Total invested

$57.6B

Ownership

89.3%

New positions

124

Closed positions

186

Increased positions

608

Reduced positions

547

Put/Call ratio

1.05

Holder	Reported	Shares	Value	Δ Qtr
BLACKROCK, INC.	8/7/2026	9.1M	$5.7B	+1.85%
VANGUARD CAPITAL MANAGEMENT LLC	8/13/2026	6.6M	$4.1B	−0.38%
DODGE & COX	8/13/2026	4.9M	$3.0B	+9.26%
STATE STREET CORP	9/22/2026	4.8M	$3.0B	+3.65%
INVESCO LTD.	8/14/2026	3.9M	$2.5B	+80.71%
JPMORGAN CHASE & CO	8/12/2026	3.8M	$2.4B	−12.47%
VANGUARD PORTFOLIO MANAGEMENT LLC	8/13/2026	3.2M	$2.0B	+84.53%
FRANKLIN RESOURCES INC	8/13/2026	2.8M	$1.7B	+1.83%
GEODE CAPITAL MANAGEMENT, LLC	8/12/2026	2.6M	$1.6B	+0.69%
NUVEEN, LLC	8/11/2026	2M	$1.3B	−2.18%
LOOMIS SAYLES & CO L P	8/14/2026	1.9M	$1.2B	−2.78%
PRICE T ROWE ASSOCIATES INC /MD/	8/14/2026	1.5M	$953.8M	−29.75%
MORGAN STANLEY	8/13/2026	1.4M	$871.5M	+5.94%
BANK OF AMERICA CORP /DE/	8/14/2026	1.3M	$805.0M	+8.53%
WELLINGTON MANAGEMENT GROUP LLP	8/14/2026	1.3M	$792.0M	−30.88%
NORGES BANK	8/12/2026	1.2M	$731.3M	—
GOLDMAN SACHS GROUP INC	8/14/2026	1.2M	$725.3M	−10.56%
AQR CAPITAL MANAGEMENT LLC	8/14/2026	1.1M	$702.2M	−8.52%
AMUNDI	8/11/2026	1M	$632.0M	+0.37%
NORTHERN TRUST CORP	8/13/2026	916.5K	$571.5M	−2.70%
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	8/14/2026	846.3K	$527.7M	+5.20%
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P.	8/14/2026	846.3K	$527.7M	—
FMR LLC	8/13/2026	832K	$518.8M	−45.20%
CAPITAL WORLD INVESTORS	8/12/2026	814.9K	$508.1M	−42.57%
LEGAL & GENERAL GROUP PLC	8/14/2026	760K	$473.9M	+3.81%

Insider transactions

Insider	Type	Transacted	Price	Date
Murphy Andrew J	S-SALE	16	$757.68	Oct 14
Murphy Andrew J	S-SALE	463	$780.63	Oct 14
Murphy Andrew J	S-SALE	12	$770.20	Oct 14
Murphy Andrew J	S-SALE	14	$759.96	Oct 14
Murphy Andrew J	S-SALE	24	$758.16	Oct 14
Murphy Andrew J	S-SALE	25	$763.76	Oct 14
Murphy Andrew J	S-SALE	27	$761.36	Oct 14
Murphy Andrew J	S-SALE	35	$755.91	Oct 14
Murphy Andrew J	S-SALE	38	$777.76	Oct 14
Murphy Andrew J	S-SALE	50	$781.47	Oct 14

Analyst consensus

Buy49 analysts

Bearish · 0 · Hold · 14 · Bullish · 35

Earnings history

	EPS	Estimate
Q3 2024	$12.46	$11.69	Beat
Q4 2024	$12.07	$11.21	Beat
Q1 2025	$8.22	$8.62	Miss
Q2 2025	$12.89	$8.43	Beat
Q3 2025	$11.83	$9.65	Beat
Q4 2025	$11.44	$10.74	Beat
Q1 2026	$9.47	$8.91	Beat
Q2 2026	$14.29	$10.16	Beat

Peers

Company overview

IPO dateApr 2, 1991

CEOLeonard S. Schleifer

Employees15,410

SectorHealthcare

IndustryBiotechnology

CountryUS

ExchangeNASDAQ Global Select

Websitewww.regeneron.com

Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.

Athenic provides research and information tools for educational purposes only and is not a registered investment adviser or broker-dealer. Nothing on this page is investment advice or a recommendation to buy or sell any security. Market data may be delayed. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal.